Aeterna Zentaris Inc. AEZS.TO
Aug 8, 2024, 3:59 PM EDT
52-week range unavailable
- Market cap
- 25.38M
- Revenue (ttm)
- 2.37M
- Shares out
- 3.06M
- Forward P/E
- -1.81
- Volume
- 1.23K
- Open
- 7.57
- Previous close
- 8.29
- Day's range
- 7.57 – 8.30
- Beta
- 2.26
Key statistics
- Enterprise value
- -19.25M
- PEG ratio
- 0.00
- Price / sales
- 10.69
- Price / book
- 0.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -99.80%
- Free cash flow
- -10.09M
- Total cash
- 29.55M
- Total debt
- 234.00K
- Return on equity
- -81.71%
- Short % of float
- 0.00%
- 50-day average
- 7.81
- 200-day average
- 7.33
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- zentaris.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on AEZS.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEMARE NICK | Director | Conversion of Exercise of derivative security | Dec 16, 2010 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.33% | 16,213 | 54.15K | Jun 29, 2023 |
| Edmond De Rothschild Holding S.A. | 0.08% | 4,000 | 13.36K | Jun 29, 2023 |
| Group One Trading, L.P. | 0.06% | 2,999 | 10.02K | Jun 29, 2023 |
| Royal Bank of Canada | 0.05% | 2,537 | 8.47K | Jun 29, 2023 |
| JP Morgan Chase & Company | 0.02% | 912 | 3.05K | Jun 29, 2023 |
| National Bank of Canada/FI | 0.01% | 348 | 1.16K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.08% | 3,659 | 13.54K | May 30, 2023 |